Literature DB >> 20118388

Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic.

David A Wetter1, Michael J Camilleri.   

Abstract

OBJECTIVE: To examine clinical, etiologic, and histologic features of Stevens-Johnson syndrome and to identify possible correlates of clinical disease severity related to etiologic and histopathologic findings. PATIENTS AND METHODS: This is a retrospective review of patients seen at Mayo Clinic between January 1, 2000, and December 31, 2007.
RESULTS: Of 27 patients (mean age, 28.1 years), 22 (81%) had involvement of 2 or more mucous membranes, and 19 (70%) had ocular involvement. Medications, most commonly antibiotics and anticonvulsants, were causative in 20 patients. Mycoplasma pneumoniae infection caused 6 of the 27 cases. Corticosteroids were the most common systemic therapy. No patients with mycoplasma-induced Stevens-Johnson syndrome had internal organ involvement or required treatment in the intensive care unit, in contrast to 4 patients each in the drug-induced group. Three patients had chronic ocular sequelae, and 1 died of complications. Biopsy specimens from 13 patients (48%) showed epidermal necrosis (8 patients), basal vacuolar change (10 patients), and subepidermal bullae (10 patients). Biopsy specimens from 11 patients displayed moderate or dense dermal infiltrate. Histologic features in drug-induced cases included individual necrotic keratinocytes, dense dermal infiltrate, red blood cell extravasation, pigment incontinence, parakeratosis, and substantial eosinophils or neutrophils.
CONCLUSION: Our clinical and etiologic findings corroborate those in previous reports. M pneumoniae-induced Stevens-Johnson syndrome manifested less severely than its drug-induced counterpart. The limited number of biopsies precludes unequivocal demonstration of histopathologic differences between drug-induced and M pneumoniae-induced Stevens-Johnson syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20118388      PMCID: PMC2813820          DOI: 10.4065/mcp.2009.0379

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  26 in total

1.  Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system.

Authors:  R Ball; L K Ball; R P Wise; M M Braun; J A Beeler; M E Salive
Journal:  Pediatr Infect Dis J       Date:  2001-02       Impact factor: 2.129

2.  Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany.

Authors:  E Schöpf; A Stühmer; B Rzany; N Victor; R Zentgraf; J F Kapp
Journal:  Arch Dermatol       Date:  1991-06

3.  Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study.

Authors:  Jürgen Schneck; Jean-Paul Fagot; Peggy Sekula; Bruno Sassolas; Jean Claude Roujeau; Maja Mockenhaupt
Journal:  J Am Acad Dermatol       Date:  2007-10-04       Impact factor: 11.527

4.  Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006.

Authors:  Yumiko Yamane; Michiko Aihara; Zenro Ikezawa
Journal:  Allergol Int       Date:  2007-09-01       Impact factor: 5.836

5.  Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome.

Authors:  Vinod K Sharma; Gomathy Sethuraman; Anil Minz
Journal:  Indian J Dermatol Venereol Leprol       Date:  2008 May-Jun       Impact factor: 2.545

6.  Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome.

Authors:  C Léauté-Labrèze; T Lamireau; D Chawki; J Maleville; A Taïeb
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

7.  Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination.

Authors:  D Dobrosavljevic; M V Milinkovic; M M Nikolic
Journal:  J Eur Acad Dermatol Venereol       Date:  1999-07       Impact factor: 6.166

8.  Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.

Authors:  Ariane Auquier-Dunant; Maja Mockenhaupt; Luigi Naldi; Osvaldo Correia; Werner Schröder; Jean-Claude Roujeau
Journal:  Arch Dermatol       Date:  2002-08

9.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.

Authors:  Maja Mockenhaupt; Cecile Viboud; Ariane Dunant; Luigi Naldi; Sima Halevy; Jan Nico Bouwes Bavinck; Alexis Sidoroff; Jürgen Schneck; Jean-Claude Roujeau; Antoine Flahault
Journal:  J Invest Dermatol       Date:  2007-09-06       Impact factor: 8.551

Review 10.  Mycoplasma pneumoniae infections and Stevens-Johnson syndrome. Report of eight cases and review of the literature.

Authors:  M Levy; N H Shear
Journal:  Clin Pediatr (Phila)       Date:  1991-01       Impact factor: 1.168

View more
  25 in total

1.  Refurbishing Mayo Clinic Proceedings: 2011-2012.

Authors:  William L Lanier
Journal:  Mayo Clin Proc       Date:  2011-01       Impact factor: 7.616

2.  Rare extrapulmonary complications of Mycoplasma pneumoniae infection.

Authors:  Kiran Dhaliwal; Kevin Enright
Journal:  BMJ Case Rep       Date:  2016-02-01

3.  Tough to Swallow: Dysphagia in a Child with an Aberrant Left Subclavian Artery.

Authors:  Diane Hsu; Brock Martin; Erna Forgó; Elton Greene; Maheen Hassan; Dorsey Bass
Journal:  Dig Dis Sci       Date:  2021-01-12       Impact factor: 3.199

4.  Evaluation of the patients diagnosed with Stevens Johnson syndrome and toxic epidermal necrolysis: a single center experience.

Authors:  Şükrü Çekiç; Yakup Canıtez; Nihat Sapan
Journal:  Turk Pediatri Ars       Date:  2016-09-01

Review 5.  Epidemiology and risk factors for drug allergy.

Authors:  Bernard Y-H Thong; Teck-Choon Tan
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

Review 6.  Bullous lesions in a patient with systemic lupus erythematosus.

Authors:  Jennifer S Ranario; Jennifer L Smith
Journal:  J Clin Aesthet Dermatol       Date:  2014-09

7.  Metolazone Associated Stevens Johnson Syndrome-Toxic Epidermal Necrolysis Overlap.

Authors:  Prabhat Kumar; Ajay Chauhan; Riyaz Charaniya; Anindya Ghosh; Vaibhav Tandon
Journal:  J Clin Diagn Res       Date:  2016-03-01

8.  Outbreak of Mycoplasma pneumoniae-Associated Stevens-Johnson Syndrome.

Authors:  Daniel Olson; Louise K Francois Watkins; Alicia Demirjian; Xia Lin; Christine C Robinson; Kristin Pretty; Alvaro J Benitez; Jonas M Winchell; Maureen H Diaz; Lisa A Miller; Teresa A Foo; Melanie D Mason; Ursula L Lauper; Oren Kupfer; Jeffrey Kennedy; Mary P Glodé; Preeta K Kutty; Samuel R Dominguez
Journal:  Pediatrics       Date:  2015-08       Impact factor: 7.124

9.  Mycoplasma pneumoniae-Induced-Stevens Johnson Syndrome: Rare Occurrence in an Adult Patient.

Authors:  Samad Rasul; Faria Farhat; Yared Endailalu; Fatima Tabassum Khan; Vishal Poddar
Journal:  Case Rep Med       Date:  2012-08-16

10.  Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study.

Authors:  Tsugumichi Sato; Ching-Lan Cheng; Heung-Woo Park; Yea-Huei Kao Yang; Min-Suk Yang; Mizuki Fujita; Yuji Kumagai; Masahiro Tohkin; Yoshiro Saito; Kimie Sai
Journal:  Clin Transl Sci       Date:  2021-01-27       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.